Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.
In their new study, the LJI scientists are the first to show that GPR25 is induced by a signaling molecule called TGF-β.
FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology ...
Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, ...
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in ...
A pioneering preclinical study has shown that CAR T cell therapy—a personalized form of immunotherapy used in cancer ...
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company ...
PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. announced it will present interim clinical data from its first-in-human ...
Tumors trigger T-cell exhaustion through a TSP-1–CD47 signaling pathway. Blocking it can restore immune strength and improve cancer treatment.
The company plans to use the proceeds to test its TCR-T-cell therapy in patients with MAGE-A4-positive solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback